A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain

Neuropathic Pain Special Interest Group of the Italian Neurological Society

Research output: Contribution to journalArticle

Abstract

To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.

Original languageEnglish
JournalNeurological Sciences
DOIs
Publication statusE-pub ahead of print - Apr 2 2019

Fingerprint

Public Opinion
Neuralgia
Consensus
Advisory Committees
Patient Care
Research
Pharmacology
Guidelines
Pain
Pharmaceutical Preparations

Cite this

A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain. / Neuropathic Pain Special Interest Group of the Italian Neurological Society.

In: Neurological Sciences, 02.04.2019.

Research output: Contribution to journalArticle

@article{1b9155ee1b794c28a073714b6c132111,
title = "A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain",
abstract = "To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when {"}the patient does not reach the 50{\%} reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose.{"} Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.",
author = "{Neuropathic Pain Special Interest Group of the Italian Neurological Society} and P Ciaramitaro and G Cruccu and {de Tommaso}, M and G Devigili and D Fornasari and P Geppetti and M Lacerenza and G Lauria and S Mameli and P Marchettini and M Nolano and E Polati and V Provitera and M Romano and C Solaro and S Tamburin and V Tugnoli and M Valeriani and Andrea Truini",
year = "2019",
month = "4",
day = "2",
doi = "10.1007/s10072-019-03870-y",
language = "English",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain

AU - Neuropathic Pain Special Interest Group of the Italian Neurological Society

AU - Ciaramitaro, P

AU - Cruccu, G

AU - de Tommaso, M

AU - Devigili, G

AU - Fornasari, D

AU - Geppetti, P

AU - Lacerenza, M

AU - Lauria, G

AU - Mameli, S

AU - Marchettini, P

AU - Nolano, M

AU - Polati, E

AU - Provitera, V

AU - Romano, M

AU - Solaro, C

AU - Tamburin, S

AU - Tugnoli, V

AU - Valeriani, M

AU - Truini, Andrea

PY - 2019/4/2

Y1 - 2019/4/2

N2 - To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.

AB - To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.

U2 - 10.1007/s10072-019-03870-y

DO - 10.1007/s10072-019-03870-y

M3 - Article

C2 - 30941628

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -